Anti-CD37 antibodies for chronic lymphocytic leukemia

Bibliography

• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012;62:220-41
   PubMed Web of Science ®Google Scholar
• Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs 2009;69:2415-49
   PubMed Web of Science ®Google Scholar
• CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999;91:861-8
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al.; German CLL study group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382-91
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French cooperative group on chronic lymphocytic leukemia. N Engl J Med 1998;338:1506-14
   PubMed Web of Science ®Google Scholar
• Schweighofer CD, Cymbalista F, Müller C, et al. Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (fcr) improves event-free survival in patients with high-risk binet stage a chronic lymphocytic leukemia – first results of a randomized german-french cooperative phase III trial. Blood 2013;122:524
   Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. International workshop on chronic lymphocytic leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood 2008;111:5446-56
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al.; German CLL study group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382-91
   PubMed Web of Science ®Google Scholar
• Knauf W. Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2009;9:165-74
   PubMed Web of Science ®Google Scholar
• Korycka-Wołowiec A, Robak T. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opin Drug Metab Toxicol 2012;8:1455-68
   PubMed Web of Science ®Google Scholar
• Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006;13:3165-89
   PubMed Web of Science ®Google Scholar
• CLL Trialists' Collaborative Group. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica 2012;97:428-36
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7
   PubMed Web of Science ®Google Scholar
• Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-9
   PubMed Web of Science ®Google Scholar
• Robak T. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncol 2013;9:69-91
   PubMed Web of Science ®Google Scholar
• Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther 2012;12:503-15
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-65
   PubMed Web of Science ®Google Scholar
• Robak T, Lech-Maranda E, Robak P. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2010;10:1529-43
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Dreyling M, Robak T, ESMO guidelines working group. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi50-4
   PubMed Web of Science ®Google Scholar
• Link MP, Bindl J, Meeker TC, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 1986;137:3013-18
   Google Scholar
• Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997;11:428-42
   PubMed Web of Science ®Google Scholar
• Classon BJ, Williams AF, Willis AC, et al. The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OX-44 antigen. J Exp Med 1989;169:1497-502
   PubMed Web of Science ®Google Scholar
• Schwartz-Albiez R, Dörken B, Hofmann W, Moldenhauer G. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 1988;140:905-14
   PubMed Web of Science ®Google Scholar
• van Spriel AB, Puls KL, Sofi M, et al. A regulatory role for CD37 in T cell prolferation. J Immunol 2004;172:2953-61
   PubMed Web of Science ®Google Scholar
• Hemler ME. Specific tetraspanin functions. J Cell Biol 2001;24:1103
   Google Scholar
• Angelisová P, Hilgert I, Horejsí V. Association of four antigens of the tetraspans family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins. Immunogenetics 1994;39:249-56
   PubMed Web of Science ®Google Scholar
• Moldenhauer G. CD37. J Biol Regul Homeost Agents 2000;14:281-3
   PubMed Web of Science ®Google Scholar
• Furman RR, Andritsos LA, Flinn IW, et al. Phase 1 dose escalation study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and refractory CLL. Blood 2010;116(Suppl 21):abstract 56
   Google Scholar
• van Spriel AB, de Keijzer S, van der Schaaf A, et al. The tetraspanin CD37 orchestrates the alpha(4)beta(1) integrin-Akt signaling axis and supports long-lived plasma cell survival. Sci Signal 2012;5:ra82
   PubMedGoogle Scholar
• Knobeloch KP, Wright MD, Ochsenbein AF, et al. Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol Cell Biol 2000;20:5363-9
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yeh YY, Wang L, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012;21:694-708
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027-38
   PubMed Web of Science ®Google Scholar
• Barrena S, Almeida J, Yunta M, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005;19:1376-83
   PubMed Web of Science ®Google Scholar
• Belov L, de la Vega O, dos Remedios CG, et al. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res 2001;61:4483-9
   PubMed Web of Science ®Google Scholar
• Press OW, Farr AG, Borroz KI, et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-12
   PubMed Web of Science ®Google Scholar
• Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83:1390-7
   PubMed Web of Science ®Google Scholar
• Baum PR, Cerveny C, Gordon B, et al. Relatively high expression of CD37 was observed on leukemic cells in CLL patients [abstract 85711009540]. Am Soc Clin Ocol Ann Meet Abstracts; 2009
   Google Scholar
• Moore K, Cooper SA, Jones DB. Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. J Pathol 1987;152:13-21
   PubMed Web of Science ®Google Scholar
• Heider KH, Kiefer K, Zenz T, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011;118:4159-68
   PubMed Web of Science ®Google Scholar
• Deckert J, Park PU, Chicklas S, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 2013;122:3500-10
   PubMed Web of Science ®Google Scholar
• Vaughan AT, Iriyama C, Beers SA, et al. Inhibitory FcgammaRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 2014;123(5):669-77
   PubMed Web of Science ®Google Scholar
• Jones EL, Demaria MC, Wright MD. Tetraspanins in cellular immunity. Biochem Soc Trans 2011;39:506-11
   PubMed Web of Science ®Google Scholar
• Krause G, Patz M, Isaeva P, et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 2012;26:546-9
   PubMed Web of Science ®Google Scholar
• Heider K-H, Kiefer K, Ostermann E, et al. Novel Fc-engineered antibodies to CD37 with pro-apoptotic and enhanced ADCC activity. Blood 2010;116:3916
   Google Scholar
• Jin L, Cambier JC. SMIP-016 in action: CD37 as a death receptor. Cancer Cell 2012;21:597-8
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs 2009;10:1383-90
   PubMed Web of Science ®Google Scholar
• Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007;110:2569-77
   PubMed Web of Science ®Google Scholar
• Flinn IW. CD37: the comeback kid. Blood 2011;118:4007-8
   PubMed Web of Science ®Google Scholar
• Cerveny CG, Grosmaire L, Nilsson C, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. J Clin Oncol 2008;26(Suppl 20):abstract 3074
   Google Scholar
• Nickerson-Nutter C, Tchistiakova L, Seth NP, et al. Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys. Rheumatology (Oxford) 2011;50:1033-44
   PubMed Web of Science ®Google Scholar
• Zhao XB, Trupti J, Lapalombella R, et al. NK cells contribute significantly to the innate immun eeffector role of CD37-specific SMIP in CLL and NHL. Blood 2006;108:abstract 135
   Google Scholar
• Zhao XB, Biswas S, Mone A, et al. Novel anti-CD37 small modular immunopharmaceutical (SMIP) induces B-cell-specific, caspase-independent apoptosis in human CLL cells. Blood 2004;104:abstract 2515
   Google Scholar
• Rafiq S, Siadak A, Butchar JP, et al. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. MAbs 2013;5:723-35
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Zhao XB, Grosmaire L, et al. CD37–SMIPTM drug induced caspase independent cellular cytotoxicity is associated with activation of phosphotyrosine-mediated signaling events in primary chronic lymphocytic leukemia (CLL) B cells. Blood (ASH Annual Meeting Abstracts) 2006;108:abstract 753
   Google Scholar
• Andritsos L, Furman R, Flinn IW, et al. A phase I trial of TRU-016, an anti- CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL. Am Soc Clin Oncol Ann Meet Abstracts 2009;27:abstract 3017
   Google Scholar
• Byrd JC, Pagel JM, Awan FT, et al. A Phase 1 study evaluating the safety and tolerability of otlertuzumab (TRU-016), an anti-CD37 mono-specific ADAPTIRTM therapeutic protein in chronic lymphocytic leukemia. Blood 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Awan FT, Pagel JM, Andritsos LA, et al. Phase 1 study of Tru-016, an anti-CD37 SMIP™ protein in naïve and relapsed and/or refractory CLL patients. Blood (ASH Annual Meeting Abstracts) 2011;118:abstract 1792
   Google Scholar
• Awan F, Jaeger U, Rifkin R, et al. Phase 1b study of TRU-016, an anti-CD37 SMIP™ protein, in combination with bendamustine vs bendamustine alone in relapsed chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 1795
   Google Scholar
• Robak T, Hellman A, Kloczko J, et al. Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIR™ protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2013;122:abstract 2860
   Web of Science ®Google Scholar
• Pagel JM, O'Brien S, Byrd JC, et al. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with rituximab in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2013;122:abstract 4165
   Google Scholar
• Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97
   PubMed Web of Science ®Google Scholar
• Link M, Bindl J, Meeker T, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol 1986;137:3013-18
   Google Scholar
• Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027-38
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696-711
   PubMed Web of Science ®Google Scholar
• Deckert J, Park PU, Chicklas S, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 2013;122:3500-10
   PubMed Web of Science ®Google Scholar
• Beck A, Lambert J, Sun M, Lin K. Fourth world antibody-drug conjugate summit: february 29-march 1, 2012, frankfurt, germany. MAbs 2012;4:637-47
   PubMedGoogle Scholar
• Park PU, Yi Y, Li M, et al. Antibody and linker selection for the anti-CD37 antibody-maytansinoid conjugate IMGN529 for the treatment of B-cell malignancies. Cancer Res 2011;71:2830
   Google Scholar
• Deckert J, Mayo MF, Yi Y, et al. IMGN529: a therapeutic maytansinoid conjugate of an anti-CD37 antibody with multiple mechanisms of action for B-cell lymphoma and leukemia. Cancer Res 2011;71:4565
   Google Scholar
• Beckwith KA, Frissora FW, Stefanovski MR, et al. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia 2014, doi:10.1038/leu.2014.32
   Web of Science ®Google Scholar
• Stephens DM, Byrd JC. Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. Hematol Oncol Clin North Am 2013;27:303-27
   PubMed Web of Science ®Google Scholar
• Muthusamy N, Beckwith KA, Frissora FW, et al. Generation and validation of a novel human CD37-positive chronic lymphocytic leukemia mouse model for pre-clinical evaluation of human CD37 directed therapeutics [abstract 4.28]. IWCLL Abstract 2013
   Google Scholar
• Dahle J, Repetto-Llamazares AH, Mollatt CS, et al. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-hodgkin's lymphoma. Anticancer Res 2013;33:85-95
   PubMed Web of Science ®Google Scholar
• Repetto-Llamazares AH, Larsen RH, Mollatt C, et al. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm 2013;6:20-7
   PubMedGoogle Scholar
• Smeland E, Funderud S, Ruud E, et al. Characterization of two murine monoclonal antibodies reactive with human B cells. Scand J Immunol 1985;21:205-14
   PubMedGoogle Scholar
• Zenz T, Gribben JG, Hallek M, et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012;119(18):4101-7
   PubMed Web of Science ®Google Scholar
• Palomba ML, Younes A. In the spotlight: a novel CD37 antibody-drug conjugate. Blood 2013;122:3397-8
   PubMed Web of Science ®Google Scholar
• Yu B, Mao Y, Yuan Y, et al. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials 2013;34:6185-93
   PubMed Web of Science ®Google Scholar
• Mao Y, Wang J, Zhao Y, et al. A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery. Nanomedicine 2013; pii: S1549-9634(13)00360, doi:10.1016/j.nano.2013.08.001
   Web of Science ®Google Scholar